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Esophageal cancer (made up primarily of squamous and adenocarcinoma) is an 
understudied, yet aggressive form of cancer, ranking sixth in the world in terms of 
mortality1. While adenocarcinoma incidence has been steadily increasing in the 
Western world in the past decades, squamous cell carcinoma (ESCC) continues to be 
the major type of oesophageal cancer in Asia. Risk factors for ESCC  include smoking, 
alcohol, drinking scalding hot beverages and poor nutrition2. For some of these risks, 
a geographical dependence can be observed; for example family history and high 
concentration of dietary nitrates are more prevalent risk factors in rural, high-
incidence areas of China, while esophageal cancer cases in urban, low incidence 
areas are more frequently associated with drinking tea at high temperature3, and 
hot-spots in the Kashmir Valley (India) relate to chewing nass4. How these factors 
differ in other parts of Asia, however, is less well understood. 
At the genetic level, inherited risk alleles in the phospholipase C-epsilon-1 enzyme 
(PLCE1, hydrolyzing phospholipids into fatty acids, affecting cell growth and 
differentiation) and susceptibility loci in chromosomes 5, 6, 10 and 12 in Chinese 
populations, as well as germline variants in alcohol dehydrogenase 1B (ADH1B) and 
aldehyde dehydrogenase 2 (ALDH2) in Japanese populations have been associated 
with ESCC, the latter increasing the risk substantially when combined with smoking 
and alcohol consumption5.  
With the advent of genome wide sequencing technologies a number of recent 
genomic studies, prevalently in Chinese populations6-9, have started to map the 
somatic landscape of ESCC. These studies have highlighted tumour suppressors like 
TP53 and CDKN2A as common drivers, with the cell cycle (e.g. CCND1), RTK-MAPK-
PI3K (e.g. PI3KCA), Notch pathways (e.g. NOTCH1), hedgehog signalling and 
epigenetic regulation also being frequent causes of mutation in this cancer. 
Inactivating mutations in genes involved in chromatin remodelling (e.g. CREBBP), 
cell-cell communication (e.g. FAT1), or transcriptional regulation (e.g. ZNF750), 
among others, have also been noted. What is lacking is a connection between the 
causative agents and the mutational landscape that is observed in ESCC. 
In the study by Sawada et al. of 144 Japanese patients, the authors investigated the 
relationship between the individual patient risk factors (alcohol, smoking and 
variants in specific inherited loci known to alter the metabolism of these 
carcinogens) and the acquired pattern of mutations in the cancer itself10. This 
includes analysis of mutations in specific genes (e.g. known cancer causing genes like 
TP53 and TGF beta) as well as elucidating “mutational signatures”. In the past few 
years, large-scale analyses have revealed many mutational signatures, or 
characteristic imprints, across the genome of human cancers 11, 12. These imprints 
are the outcome of multiple mutagenic processes that have been operating in all 
cells of the human body during the lifetime of the patient. They are a combined 
consequence of ageing, exposures to mutagens like tobacco and UV light for 
example, as well as intrinsic or acquired defects in DNA repair machinery. The profile 
of each signature is displayed using the six possible base-substitutions: C>A, C>G, 
C>T, T>A, T>C, and T>G (referred to by the pyrimidine of the mutated Watson–Crick 
base pair). Further information is then obtained by incorporating information on the 
bases immediately 5’ and 3’ to each mutated base generating 96 possible mutation 
types: 6 types of substitution ∗ 4 types of 5’ base ∗ 4 types of 3’ base. Mutational 
signatures are then reported based on the observed trinucleotide frequency of the 
human genome. By examining these signatures in thousands of cancer genomes it is 
possible to start attributing causality13. 
In Japanese patients with ESCC10 the authors identified three clusters of patients. 
Cluster 1 patients have a predominant APOBEC signature characterised by C>G/T 
substitutions with an adjacent 5’ thymine. APOBEC is a cytosine deaminase enzyme 
which converts cytosine to uracil and may induce mutation into tumours.  In keeping 
with this, tumours in cluster 1 have a relatively high mutation rate across their 
genome. Cluster 3 patients also have a high proportion of APOBEC as well as a CpG 
signature characterised by C>T substitutions at CpG dinucleotides. Neither of these 
signatures was predominant in cluster 2.  
Interestingly, these clusters were also shown to carry environmental and genetic 
associations: for example, heavy drinking in patients with the inherited ALDH2 risk 
allele were enriched in clusters 1 and 2, and somatic mutations in a potential tumour 
suppressor ZNF7507 and PIK3CA signalling molecule mutations were also prevalent 
in the first cluster (containing a more prominent APOBEC signature). 
The authors also undertook a concerted effort to compare the genomic profiles of 
ESCC in Japanese and Chinese populations (high and low incidence areas). They 
found that alcohol intake and smoking behaviour were more strongly associated 
with the incidence of this disease in Japan compared to China - also previously 
reported by e.g. Lin et al.3 - but otherwise mutational spectra, driver genes (TP53, 
ZNF750, NOTCH1) and pathways seemed to be conserved across Japanese and 
Chinese cohorts. Of note, the association between the APOBEC signature and 
mutations in ZNF750 was preserved among the different populations. Extending to a 
pan-cancer type study including head-and-neck and lung squamous cell carcinoma, 
similar signature profiles were observed, but different from oesophageal 
adenocarcinoma, emphasizing again the fundamentally different carcinogenic 
mechanism of the latter. 
Sawada et al. also highlighted TET2 as a new mutational target in ESCC occurring in 
around 6% of their cohort. This gene has roles in cell invasion and mutations were 
related to poor prognosis. This is interesting, especially in view of recent work that 
relates miR-22 to TET2 in the promotion of stem cell transformation 14. The same 
microRNA has also been shown to inhibit tumour growth and metastasis in gastric 
cancer through MMP14 and Snail targeting 15. These studies suggest that TET2 and 
its regulatory (especially miRNA) network constitute targets worthy of further 
investigation in ESCC. At the pathway level, disruption of epigenetic regulation was 
highlighted as one of the dominant mechanisms in this cohort (affecting 59% of the 
patients), with an important role of repressive epigenetic marks in the pathogenesis 
of ESCC.  
In terms of what this study adds to our understanding, the mutational signature 
analysis performed here builds upon the work of Zhang et al9, who were the first to 
document the signature related to the APOBEC family of cytidine deaminases and 
the CpG signature in ESCC. Importantly, however, the study by Sawada et al shows 
that the various contributions of mutational processes in this cancer reveal 
subgroups of distinct aetiology, and these are informative of the different 
environmental influences and genetic predispositions in this disease (Figure 1). 
APOBEC mRNA deregulation has been linked to the APOBEC signature in a variety of 
cancers and was suggested to contribute to carcinogenesis16. Considering that 
cluster 1 displays a relatively high contribution of the APOBEC signature, as well as 
significantly more mutations in ZNF750, it will be interesting to see future studies 
into the molecular mechanism of this process in this ESCC subgroup. 
Furthermore, the study highlights the importance of environmental risk factors to 
the development of ESCC and the fact that this can differ significantly even within 
territories of close geographical proximity. It is thus imperative to collect detailed 
exposure data in large-scale genomic cancer studies such as the International Cancer 
Genome Consortium to enable these inferences to be made. 
From a therapeutic perspective, it is encouraging to observe that this diversity in risk 
factors is not reflected to the same extent at the genomic level, with driver genes 
and pathways being overall conserved among Chinese and Japanese populations. 
Recent studies in other cancers have highlighted the potential of mutational 
signature-based stratification in the clinic. It has been suggested, for instance, that 
gastric tumours with homologous recombination (BRCA-signature related) defects 
might benefit from platinum/PARP inhibitors therapy17. Further research is needed 
to elucidate the applicability of this type of classification for early detection, 
prognosis or treatment of ESCC, especially since the mutational spectra and 
subgroup profiles seem to be maintained throughout Chinese and Japanese 
populations – and thus, would offer a promising strategy universally applicable in 
this cancer. 
 
 
Figure 1. Aetiology and classification of ESCC in Japanese populations. Risk factors 
include alcohol consumption, smoking and germline variants in alcohol metabolism-
related enzymes (ALDH1B, ALDH2), among others. These imprint mutational 
patterns in the genome that promote carcinogenesis, along with dysregulation of 
key driver genes: TP53, CDKN2A, CCND1, NOTCH1, PIK3CA, ZNF750 etc. The 
signatures of such mutational processes can be decomposed according to their 
trinucleotide substitution context (peaks of mutations for each substitution 
category, C>[A,G,T], T>[A,C,G], are shown), resulting in an APOBEC-related pattern, a 
CpG-predominant one, and other mixed patterns. The different contributions of 
these signatures help distinguish three main subgroups of patients with ESCC in this 
population (denoted by different colours: orange, green, purple), and these 
subgroups differ in their associated risk factors and genomic landscape.  
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